Toward a neuroimaging treatment selection biomarker for major depressive disorder.

ABSTRACT:

Importance

Currently, fewer than 40% of patients treated for major depressive disorder achieve remission with initial treatment. Identification of a biological marker that might improve these odds could have significant health and economic impact.

Objective

To identify a candidate neuroimaging "treatment-specific biomarker" that predicts differential outcome to either medication or psychotherapy.

Design

Brain glucose metabolism was measured with positron emission tomography prior to treatment randomization to either escitalopram oxalate or cognitive behavior therapy for 12 weeks. Patients who did not remit on completion of their phase 1 treatment were offered enrollment in phase 2 comprising an additional 12 weeks of treatment with combination escitalopram and cogniti

SUBMITTER: McGrath CL 

PROVIDER: S-EPMC4413467 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature